Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
XFOR
#3050
X4 Pharmaceuticals, Inc. - Common Stock
4.2
3
USD
+0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.44%
Monthly Change
+7.63%
6 month change
+27.60%
Year Change
+42.42%
Previous Close
4.1
7
Open
4.2
3
Low
4.2
3
High
4.2
3
Volume
31
Markets
US Stock Market
Healthcare
Biotechnology
XFOR
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
579.48 K
1.03 M
4.07 M
5.6 M
5.79 M
90.92 M
99.15 M
Valuation ratios
Enterprise value
33.07 M
22.7 M
28.8 M
103.51 M
71.7 M
146.63 M
223.8 M
Price to earnings ratio
—
—
-0.63
-1.55
-3.86
-2.14
3.33
Price to sales ratio
—
—
—
804.44
57.68
26.03
32.46
Price to cash flow ratio
—
—
-0.79
1.63
1.13
-1.98
-3.18
Price to book ratio
—
—
0.82
3.07
6.66
0.91
0.5
Enterprise value to EBITDA ratio
-0.56
-0.27
-0.33
-0.97
-2.01
-3.02
-5.33
Profitability ratios
Return on assets %
-0.51
-0.76
-0.6
-0.69
-0.26
-0.27
-0.06
Return on equity %
-0.85
-1.38
-1.27
-1.98
-1.69
-0.43
-0.1
Return on invested capital %
-657.58
-951.82
-1 155.87
-1 543.03
-467.25
-1 145.98
-200.35
Gross margin %
100
—
—
100
68.83
11.43
32.63
Operating margin %
-1 995.8
—
—
-55.14 K
-1 423.58
-1 336.66
-682.96
EBITDA margin %
-1 984.1
—
—
-54.82 K
-1 392.45
-746.2
-289.83
Net margin %
-2 071.03
—
—
-51.88 K
-1 464.61
-1 218.45
-673.21
Liquidity ratios
Quick ratio
—
—
—
—
3.33
9.98
11.02
Current ratio
6.97
6.27
5.76
5.34
3.41
10.16
11.3
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.02
0
0
0
0.02
0.02
0.01
Solvency ratios
Debt to assets ratio
—
0.28
0.21
0.37
—
—
—
Debt to equity ratio
—
0.51
0.44
1.07
—
—
—
Long term debt to total assets ratio
0.26
0.28
0.21
0.37
0.51
0.26
0.3
Long term debt to total equity ratio
0.45
0.5
0.44
1.08
3.39
0.4
0.48
Per share metrics
Operating cash flow per share
—
—
-36.41
-16.28
-19.53
-2.02
-1.33
EBIT per share
—
—
-41.35
-18.11
-5.43
-1.18
-0.82
EBITDA per share
—
—
-41.11
-18.04
-5.31
-1.15
-0.8
Total debt per share
—
—
15.88
9.21
—
—
—
Cash per share
—
—
57.48
19.27
15.23
5.98
1.65
Net current asset value per share
—
—
60.77
20.6
16.74
6.18
1.73
Tangible book value per share
—
—
34.97
8.62
3.3
3.78
0.99
Working capital per share
—
—
50.22
16.74
11.83
5.58
1.58
Book value per share
—
—
34.97
8.62
3.3
4.4
1.23
News
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology
Guggenheim initiates X4 Pharmaceuticals stock with buy rating
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval